Bioadaptives, Inc. financial data

Symbol
BDPT on OTC
Industry
Pharmaceutical Preparations
Location
2620 Regatta Drive, Suite 102, Las Vegas, NV
State of incorporation
Delaware
Fiscal year end
December 31
Former names
APEX 8 Inc. (to 8/19/2013)
Latest financial report
10-Q - Q2 2024 - Aug 19, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 4.29 % +136%
Quick Ratio 0.67 % +55.4%
Debt-to-equity -108 % -5.56%
Return On Equity 47.4 % +2.31%
Return On Assets -616 % +73.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1.23B shares +58.6%
Common Stock, Shares, Outstanding 1.23B shares +114%
Entity Public Float 358K USD
Common Stock, Value, Issued 123K USD +114%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 35.5K USD +172%
Cost of Revenue 24.1K USD +269%
General and Administrative Expense 111K USD +26.4%
Operating Income (Loss) -93K USD -66.2%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -367K USD +25.4%
Net Income (Loss) Attributable to Parent -771K USD -4.81%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 60.8K USD -26.7%
Marketable Securities, Current 0 USD -100%
Inventory, Net 6K USD -7.51%
Assets, Current 8.74K USD -81.3%
Intangible Assets, Net (Excluding Goodwill) 18K USD
Assets 8.74K USD -81.9%
Accounts Payable, Current 3.34K USD -37.4%
Accrued Liabilities, Current 153K USD +10671%
Liabilities, Current 1.93M USD +11.8%
Liabilities 1.93M USD +11.8%
Retained Earnings (Accumulated Deficit) -8.75M USD -9.66%
Stockholders' Equity Attributable to Parent -1.92M USD -14.5%
Liabilities and Equity 8.74K USD -81.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -41.2K USD -112%
Net Cash Provided by (Used in) Financing Activities 0 USD -100%
Common Stock, Shares Authorized 1.25B shares 0%
Common Stock, Shares, Issued 1.23B shares +114%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -27.1K USD -238%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 235 USD -99.4%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD
Deferred Tax Assets, Valuation Allowance 585K USD +11.4%
Deferred Tax Assets, Operating Loss Carryforwards 585K USD +11.4%
Preferred Stock, Shares Authorized 10M shares 0%
Additional Paid in Capital 6.71M USD +7.39%
Amortization of Intangible Assets 46.8K USD +619%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Interest Expense 132K USD -53.9%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%